Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Testing effectiveness (Phase 2)Study completedNCT02731352
What this trial is testing

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01706458
What this trial is testing

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 18
Large-scale testing (Phase 3)Looking for participantsNCT06745908
What this trial is testing

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Who this might be right for
NSCLC Stage IV
ImmunityBio, Inc. 507
Very early researchNot Yet RecruitingNCT07609225
What this trial is testing

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Wisconsin, Madison 15
Testing effectiveness (Phase 2)UnknownNCT05156450
What this trial is testing

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-ResistantDrug Therapy, Combination
West China Hospital 30
Not applicableUnknownNCT04833517
What this trial is testing

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Who this might be right for
Prostate Cancer MetastaticCastration Resistant Prostatic CancerAdvanced Prostate Carcinoma
Universität des Saarlandes 500
Testing effectiveness (Phase 2)Looking for participantsNCT06236139
What this trial is testing

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Fred Hutchinson Cancer Center 48
Early research (Phase 1)Ended earlyNCT07121244
What this trial is testing

68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer
Radionetics Oncology 11
Large-scale testing (Phase 3)WithdrawnNCT00691899
What this trial is testing

Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Who this might be right for
Prostate Cancer
Merck Sharp & Dohme LLC
Not applicableStudy completedNCT03563014
What this trial is testing

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 164
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)UnknownNCT03356444
What this trial is testing

Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerDrug
West China Hospital 140
Testing effectiveness (Phase 2)Looking for participantsNCT06145633
What this trial is testing

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Fred Hutchinson Cancer Center 15
Not applicableUnknownNCT04746300
What this trial is testing

ImPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS

Who this might be right for
Metastatic Prostate Cancer
Radboud University Medical Center 400
Testing effectiveness (Phase 2)Study completedNCT00891930
What this trial is testing

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Who this might be right for
Metastatic Colorectal Cancer
NantBioScience, Inc. 74
Large-scale testing (Phase 3)UnknownNCT05627752
What this trial is testing

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Zhongnan Hospital 120
Early research (Phase 1)Study completedNCT04786847
What this trial is testing

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 30
Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Testing effectiveness (Phase 2)Study completedNCT00077363
What this trial is testing

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

Who this might be right for
Recurrent Breast CancerStage IV Breast Cancer
National Cancer Institute (NCI) 70
Next Page